Envas H Tablet

Envas H Tablet is used for: Hypertension, Heart Failure

Oral Hypertension Adult: 10-40 mg/12.5-50 mg (enalapril/HCTZ)/day PO qDay or divided q12hr Chronic heart failure Adult: Enalapril maleate-10mg+ Hydrochlorothiazide-25mg (tablets) 1/2-1 tab daily. Elderly: Cautious use

Renal Impairment Severe (CrCl <30 mL/min) : Not recommended; use loop diuretic instead CrCl >30 mL/min: No dose adjustment necessary

May be taken with or without food.

Hypersensitivity to ACE inhibitors, thiazides or sulfonamides ACE-inibitor induced angioedema, hereditary or idiopathic angioedema Pregnancy (2nd and 3rd trimesters): significant risk of fetal/neonatal morbidity and mortality (due to enalapril) Renal stenosis or anuria Do not coadminister with aliskiren in patients with diabetes

Begin combination therapy only after failed monotherapy Severe renal impairment, hepatic impairment Risk of hypotension, especially in CHF patients Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy Angioedema of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors If laryngeal stridor or angioedema of the face, tongue, or glottis occurs discontinue therapy and institute appropriate therapy immediately Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors Cholestatic jaundice may occur, which may progress to fulminant hepatic necrosis; discontinue Dry hacking nonproductive cough may occur within few months of treatment; consider other causes of cough prior to discontinuation Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium sparing diuretics and potassium supplements; use cautiously if at all with these agents Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia Hydrochlorothiazide may precipitate gout in patients with familial predisposition to gout or chronic renal failure Symptomatic hypotension with or without syncope can occur with Ace inhibitors; mostly observed in volume depleted patients, correct volume depletion prior to initiation; monitor closely when initiating and increasing dosing Agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia reported with other ACE inhibitor; patients with renal impairment are at high risk; monitor CBC with differential in these patients Photosensitization may occur Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma that may occur within hours of initiating therapy; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain; additional treatment may be needed if uncontrolled intraocular pressure persists Use caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia Use hydrochlorothiazide with caution in patients with diabetes or at risk of diabetes; may see increase in glucose Use caution in patients collagen vascular disease, especially in patients with concomitant renal impairment Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia Increased cholesterol and triglyceride levels reported with thiazides; use caution in patients with moderate to high cholesterol concentrations Pathologic changes in parathyroid glands with hypercalcemia and hypophosphatemia reported with prolonged use; discontinue prior to testing for parathyroid function Lactation: enters breast milk/not recommended

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)

Significant increase in serum K levels with K supplements and K sparing diuretics. Lithium toxicity in patients receiving lithium concomitantly. Alcohol, barbiturates, narcotics potentiate orthostatic hypotension. Dosage adjustment of antidiabetic drugs needed. Potentiation of action of other antihypertensives, corticosteroids, ACTH.

Side effects of Enalapril + Hydrochlorothiazide : 1-10% Enalapril Dizziness (4-8%),Hypotension (0.9-6.7%),Headache (2-5%),Chest pain (2%),Cough (1-2%),Rash (1.5%) Hydrochlorothiazide Hypotension,Anorexia,Epigastric distress,Hypokalemia,Phototoxicity

Enalapril is an ACE inhibitor, which reduces the levels of AT II and aldosterone. This action is potentiated by Na depletion which activates the renin-angiotensin-aldosterone system. Hydrochlorothiazide also eliminates the vol factor commonly occuring with long term use of vasodilators.

Envas H 5mg + 12.5mg Tablet manufactured by Cadila Pharmaceuticals Limited.. Its generic name is Enalapril + Hydrochlorothiazide. Envas H is availble in Nepal. Farmaco Nepal drug index information on Envas H Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.